Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ernexa Therapeutics Inc.ERNA · Entity 8278 | Sr. VP of Finance | June 21, 2025 | July 08, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ernexa Therapeutics Inc.
Report date June 21, 2025 · Filed July 08, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 110 |
Reported balance
After 2025-06-21 transaction · row 1
1 source rowRow 1 · 2025-06-21 · Exercise / conversion · Acquired 30 · Balance 110 F1: Each restricted stock unit converts into one share of common stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-06-21 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-06-21 · Exercise / conversion · Acquired 30 · Balance 0 F1: Each restricted stock unit converts into one share of common stock. F2: On June 21, 2021, the reporting person was granted 118 restricted stock units, vesting in four substantially equal installments beginning on the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit converts into one share of common stock.
F2: On June 21, 2021, the reporting person was granted 118 restricted stock units, vesting in four substantially equal installments beginning on the first anniversary of the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 21, 2025 Filed Jul 8, 2025 00:00 UTC | Ernexa Therapeutics Inc. ERNA · Entity 8278 | Exercise / conversionRestricted Stock Units · Derivative | 30 | $0.00 | $0.00 |
DisclosureSEC source: 0001641172-25-018063 · ownership.xml · derivative · entry 2 Gurrola Sandra M · CIK 0001618457 · Sr. VP of Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock. F2 · derivative.exercise_date: On June 21, 2021, the reporting person was granted 118 restricted stock units, vesting in four substantially equal installments beginning on the first anniversary of the grant date. F2 · derivative.expiration_date: On June 21, 2021, the reporting person was granted 118 restricted stock units, vesting in four substantially equal installments beginning on the first anniversary of the grant date. Read SEC document |
| June 21, 2025 Filed Jul 8, 2025 00:00 UTC | Ernexa Therapeutics Inc. ERNA · Entity 8278 | Exercise / conversionCommon Stock | 30 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001641172-25-018063 · ownership.xml · nonDerivative · entry 1 Gurrola Sandra M · CIK 0001618457 · Sr. VP of Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit converts into one share of common stock. Read SEC document |
| February 07, 2025 Filed Feb 11, 2025 00:00 UTC | Ernexa Therapeutics Inc. ERNA · Entity 8278 | GrantStock Option (Right to buy) · Derivative | 150,000 | $0.00 Strike: $0.34 | $0.00 |
DisclosureSEC source: 0001493152-25-005721 · ownership.xml · derivative · entry 1 Gurrola Sandra M · CIK 0001618457 · Sr. VP of Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2035-02-07 F1 · derivative.exercise_date: Subject to continued service, one-third of the shares underlying the stock option will vest on the first anniversary of the grant date, and the remaining shares underlying the stock option will vest in 24 substantially equal monthly installments thereafter. Read SEC document |
| June 21, 2024 Filed Jun 25, 2024 20:32 UTC | Ernexa Therapeutics Inc. ERNA · Entity 8278 | Exercise / conversionRestricted Stock Units · Derivative | 437 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-24-025105 · ownership.xml · derivative · entry 3 Gurrola Sandra M · CIK 0001618457 · Sr. VP of Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 437 Underlying: Common Stock · 437 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock. F2 · derivative.exercise_date: On June 21, 2021, the reporting person was granted 1,750 restricted stock units, vesting in four substantially equal installments beginning on the first anniversary of the grant date. F2 · derivative.expiration_date: On June 21, 2021, the reporting person was granted 1,750 restricted stock units, vesting in four substantially equal installments beginning on the first anniversary of the grant date. Read SEC document |
| June 21, 2024 Filed Jun 25, 2024 20:32 UTC | Ernexa Therapeutics Inc. ERNA · Entity 8278 | Tax withholdingCommon Stock | 180 | $1.94 | $349.20 |
DisclosureSEC source: 0001493152-24-025105 · ownership.xml · nonDerivative · entry 2 Gurrola Sandra M · CIK 0001618457 · Sr. VP of Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,185 Read SEC document |
| June 21, 2024 Filed Jun 25, 2024 20:32 UTC | Ernexa Therapeutics Inc. ERNA · Entity 8278 | Exercise / conversionCommon Stock | 437 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-24-025105 · ownership.xml · nonDerivative · entry 1 Gurrola Sandra M · CIK 0001618457 · Sr. VP of Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,365 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit converts into one share of common stock. Read SEC document |
| April 26, 2024 Filed Apr 29, 2024 20:30 UTC | Ernexa Therapeutics Inc. ERNA · Entity 8278 | GrantStock Option (Right to buy) · Derivative | 80,000 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001140361-24-023012 · form4.xml · derivative · entry 1 Gurrola Sandra M · CIK 0001618457 · Sr. VP of Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2034-04-26 F1 · derivative.exercise_date: The stock option shall vest in an initial installment of one-third on the one-year anniversary of the grant date, and the remaining shares shall vest in 24 substantially equal monthly installments thereafter. Read SEC document |
| June 21, 2023 Filed Jun 24, 2023 00:30 UTC | Ernexa Therapeutics Inc. ERNA · Entity 8278 | Exercise / conversionRestricted Stock Units · Derivative | 438 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-031258 · form4.xml · derivative · entry 3 Gurrola Sandra M · CIK 0001618457 · Vice President of Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 874 Underlying: Common Stock · 438 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock. F2 · derivative.exercise_date: On June 21, 2021, the reporting person was granted 1,750 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. F2 · derivative.expiration_date: On June 21, 2021, the reporting person was granted 1,750 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. Read SEC document |
| June 21, 2023 Filed Jun 24, 2023 00:30 UTC | Ernexa Therapeutics Inc. ERNA · Entity 8278 | Tax withholdingCommon Stock | 179 | $2.48 | $443.92 |
DisclosureSEC source: 0001140361-23-031258 · form4.xml · nonDerivative · entry 2 Gurrola Sandra M · CIK 0001618457 · Vice President of Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 928 Read SEC document |
| June 21, 2023 Filed Jun 24, 2023 00:30 UTC | Ernexa Therapeutics Inc. ERNA · Entity 8278 | Exercise / conversionCommon Stock | 438 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-23-031258 · form4.xml · nonDerivative · entry 1 Gurrola Sandra M · CIK 0001618457 · Vice President of Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,107 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit converts into one share of common stock. Read SEC document |
| June 21, 2022 Filed Jun 24, 2022 00:31 UTC | Ernexa Therapeutics Inc. BTX · Entity 8278 | Exercise / conversionRestricted Stock Units · Derivative | 8,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-023928 · form4.xml · derivative · entry 3 Gurrola Sandra M · CIK 0001618457 · Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,250 Underlying: Common Stock · 8,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock. F2 · derivative.exercise_date: On June 21, 2021, the reporting person was granted 35,000 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. F2 · derivative.expiration_date: On June 21, 2021, the reporting person was granted 35,000 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. Read SEC document |
| June 21, 2022 Filed Jun 24, 2022 00:31 UTC | Ernexa Therapeutics Inc. BTX · Entity 8278 | Tax withholdingCommon Stock | 3,586 | $0.48 | $1,708.73 |
DisclosureSEC source: 0001140361-22-023928 · form4.xml · nonDerivative · entry 2 Gurrola Sandra M · CIK 0001618457 · Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,367 Read SEC document |
| June 21, 2022 Filed Jun 24, 2022 00:31 UTC | Ernexa Therapeutics Inc. BTX · Entity 8278 | Exercise / conversionCommon Stock | 8,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-22-023928 · form4.xml · nonDerivative · entry 1 Gurrola Sandra M · CIK 0001618457 · Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,953 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit converts into one share of common stock. Read SEC document |
| March 11, 2022 Filed Mar 16, 2022 01:34 UTC | Ernexa Therapeutics Inc. BTX · Entity 8278 | GrantStock Option (Right to buy) · Derivative | 114,500 | $0.00 Strike: $1.93 | $0.00 |
DisclosureSEC source: 0001140361-22-009663 · form4.xml · derivative · entry 1 Gurrola Sandra M · CIK 0001618457 · Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,500 Underlying: Common Stock · 114,500 shares Expires 2032-03-11 F1 · derivative.exercise_date: The options vest and become exercisable over three years, with 25% of the options vesting on the one-year anniversary of the grant date and the remaining options vesting in 24 substantially equal monthly installments thereafter. Read SEC document |
| March 11, 2022 Filed Mar 18, 2022 01:00 UTC Amendment | Ernexa Therapeutics Inc. BTX · Entity 8278 | GrantStock Option (Right to buy) · Derivative | 114,500 | $0.00 Strike: $1.93 | $0.00 |
DisclosureSEC source: 0001140361-22-009983 · form4.xml · derivative · entry 1 Gurrola Sandra M · CIK 0001618457 · Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,500 Underlying: Common Stock · 114,500 shares Expires 2032-03-11 F1 · derivative.exercise_date: The options vest and become exercisable in 36 substantially equal monthly installments from the grant date. Read SEC document |
| June 21, 2021 Filed Jun 22, 2021 22:01 UTC | Ernexa Therapeutics Inc. BTX · Entity 8278 | GrantRestricted Stock Unit · Derivative | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-21-021928 · form4.xml · derivative · entry 1 Gurrola Sandra M · CIK 0001618457 · Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F2 · derivative.exercise_date: The option vests and becomes exercisable in four equal installments on June 21 of each of 2022, 2023, 2024 and 2025, provided they shall vest in full immediately prior to a Change in Control (as defined in Ms. Gurrola's Executive Employment Agreement, dated as of June 16, 2021 and effective as of June 21, 2021), subject to continued service through each vesting date. F2 · derivative.expiration_date: The option vests and becomes exercisable in four equal installments on June 21 of each of 2022, 2023, 2024 and 2025, provided they shall vest in full immediately prior to a Change in Control (as defined in Ms. Gurrola's Executive Employment Agreement, dated as of June 16, 2021 and effective as of June 21, 2021), subject to continued service through each vesting date. Read SEC document |
| March 24, 2021 Filed Mar 27, 2021 01:53 UTC | Ernexa Therapeutics Inc. BTX · Entity 8278 | Tax withholdingCommon Stock | 6,094 | $2.67 | $16,270.98 |
DisclosureSEC source: 0001140361-21-010363 · form4.xml · nonDerivative · entry 1 Gurrola Sandra M · CIK 0001618457 · Former SVP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,617 F1 · shares: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units that occurred in connection with the closing of the merger (the "Merger") contemplated by the Agreement and Plan of Merger and Reorganization (the "Merger Agreement") by and among NTN Buzztime Inc., BIT Merger Sub, Inc. and Brooklyn Immunotherapeutics LLC. The number of shares withheld was determinable on March 24, 2021. No shares were sold in connection with this transaction. None of the share amounts in this Form 4 reflect the 2 for 1 reverse stock split implemented by the issuer on March 25, 2021 in connection with the Merger. Read SEC document |
| March 19, 2021 Filed Mar 22, 2021 23:00 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | Tax withholdingCommon Stock | 116 | $3.53 | $409.48 |
DisclosureSEC source: 0001493152-21-006563 · ownership.xml · nonDerivative · entry 1 Gurrola Sandra M · CIK 0001618457 · SVP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,711 F1 · shares: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. The number of shares to be withheld was determinable on March 19, 2021. No shares were sold in connection with this transaction. Read SEC document |
| February 19, 2021 Filed Feb 22, 2021 22:30 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | Tax withholdingCommon Stock | 115 | $4.81 | $553.15 |
DisclosureSEC source: 0001493152-21-004520 · ownership.xml · nonDerivative · entry 1 Gurrola Sandra M · CIK 0001618457 · SVP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,827 F1 · shares: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. The number of shares to be withheld was determinable on February 19, 2021. No shares were sold in connection with this transaction. Read SEC document |
| January 19, 2021 Filed Jan 20, 2021 22:30 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | Tax withholdingCommon Stock | 1,400 | $2.55 | $3,570.00 |
DisclosureSEC source: 0001493152-21-001453 · ownership.xml · nonDerivative · entry 1 Gurrola Sandra M · CIK 0001618457 · SVP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,942 F1 · shares: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. The number of shares to be withheld was determinable on January 19, 2021. No shares were sold in connection with this transaction. Read SEC document |
| December 19, 2020 Filed Dec 22, 2020 01:00 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | Tax withholdingCommon Stock | 100 | $2.17 | $217.00 |
DisclosureSEC source: 0001493152-20-024074 · ownership.xml · nonDerivative · entry 1 Gurrola Sandra M · CIK 0001618457 · SVP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,342 F1 · shares: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. The number of shares to be withheld was determinable on December 19, 2020. No shares were sold in connection with this transaction. Read SEC document |
| November 20, 2020 Filed Nov 20, 2020 23:00 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | Tax withholdingCommon Stock | 98 | $1.88 | $184.24 |
DisclosureSEC source: 0001493152-20-022147 · ownership.xml · nonDerivative · entry 1 Gurrola Sandra M · CIK 0001618457 · SVP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,442 F1 · shares: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. The number of shares to be withheld was determinable on November 20, 2020. No shares were sold in connection with this transaction. Read SEC document |
| October 21, 2020 Filed Oct 22, 2020 00:00 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | Tax withholdingCommon Stock | 1,178 | $2.05 | $2,414.90 |
DisclosureSEC source: 0001493152-20-019770 · ownership.xml · nonDerivative · entry 1 Gurrola Sandra M · CIK 0001618457 · SVP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,540 F1 · shares: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. The number of shares to be withheld was determinable on October 21, 2020. No shares were sold in connection with this transaction. Read SEC document |
| September 22, 2020 Filed Sep 23, 2020 23:15 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | Tax withholdingCommon Stock | 97 | $1.99 | $193.03 |
DisclosureSEC source: 0001493152-20-018250 · ownership.xml · nonDerivative · entry 1 Gurrola Sandra M · CIK 0001618457 · SVP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,718 F1 · shares: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. The number of shares to be withheld was determinable on September 22, 2020. No shares were sold in connection with this transaction. Read SEC document |
| August 25, 2020 Filed Aug 26, 2020 23:05 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | Tax withholdingCommon Stock | 98 | $2.62 | $256.76 |
DisclosureSEC source: 0001493152-20-016789 · ownership.xml · nonDerivative · entry 1 Gurrola Sandra M · CIK 0001618457 · SVP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,815 F1 · shares: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. The number of shares to be withheld was determinable on August 25, 2020. No shares were sold in connection with this transaction. Read SEC document |
| July 28, 2020 Filed Jul 28, 2020 22:00 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | Tax withholdingCommon Stock | 1,178 | $1.85 | $2,179.30 |
DisclosureSEC source: 0001493152-20-014118 · ownership.xml · nonDerivative · entry 1 Gurrola Sandra M · CIK 0001618457 · SVP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,913 F1 · shares: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. The number of shares to be withheld was determinable on July 28, 2020. No shares were sold in connection with this transaction. Read SEC document |
| June 29, 2020 Filed Jun 30, 2020 20:30 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | Tax withholdingCommon Stock | 97 | $3.15 | $305.55 |
DisclosureSEC source: 0001493152-20-012284 · ownership.xml · nonDerivative · entry 1 Gurrola Sandra M · CIK 0001618457 · SVP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,091 F1 · shares: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. The number of shares to be withheld was determinable on June 29, 2020. No shares were sold in connection with this transaction. Read SEC document |
| May 20, 2020 Filed May 20, 2020 23:12 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | Tax withholdingCommon Stock | 115 | $1.55 | $178.25 |
DisclosureSEC source: 0001493152-20-009579 · ownership.xml · nonDerivative · entry 1 Gurrola Sandra M · CIK 0001618457 · SVP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,188 F1 · shares: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. The number of shares to be withheld was determinable on May 20, 2020. No shares were sold in connection with this transaction. Read SEC document |
| April 21, 2020 Filed Apr 22, 2020 12:01 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | Tax withholdingCommon Stock | 1,392 | $1.21 | $1,684.32 |
DisclosureSEC source: 0001493152-20-006884 · ownership.xml · nonDerivative · entry 1 Gurrola Sandra M · CIK 0001618457 · SVP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,303 F1 · shares: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. The number of shares to be withheld was determinable on April 21, 2020. No shares were sold in connection with this transaction. Read SEC document |
| March 25, 2020 Filed Mar 26, 2020 01:07 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | Tax withholdingCommon Stock | 114 | $1.48 | $168.72 |
DisclosureSEC source: 0001493152-20-004751 · ownership.xml · nonDerivative · entry 1 Gurrola Sandra M · CIK 0001618457 · SVP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,695 F1 · shares: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. The number of shares to be withheld was determinable on March 25, 2020. No shares were sold in connection with this transaction. Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 13:00 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | Tax withholdingCommon Stock | 115 | $2.05 | $235.75 |
DisclosureSEC source: 0001493152-20-002967 · ownership.xml · nonDerivative · entry 1 Gurrola Sandra M · CIK 0001618457 · SVP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,809 F1 · shares: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. The number of shares to be withheld was determinable on February 25, 2020. No shares were sold in connection with this transaction. Read SEC document |
| January 29, 2020 Filed Feb 1, 2020 01:00 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | Tax withholdingCommon Stock | 114 | $2.43 | $277.02 |
DisclosureSEC source: 0001493152-20-001470 · ownership.xml · nonDerivative · entry 2 Gurrola Sandra M · CIK 0001618457 · SVP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,924 F2 · shares: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. The number of shares to be withheld was determinable on January 29, 2020. No shares were sold in connection with this transaction. Read SEC document |
| January 19, 2020 Filed Feb 1, 2020 01:00 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-20-001470 · ownership.xml · nonDerivative · entry 1 Gurrola Sandra M · CIK 0001618457 · SVP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,038 F1 · shares: Represents shares subject to a restricted stock unit award granted under the NTN Buzztime, Inc. 2019 Performance Incentive Plan. The award will vest as to 12.5% of the shares subject to the award on the three-month anniversary of the grant date and on each three month anniversary thereafter in substantially equal installments, in each case, subject to the reporting person's continued service to the issuer as of the applicable vesting date. Read SEC document |
| December 19, 2019 Filed Dec 20, 2019 22:00 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | Tax withholdingCommon Stock | 94 | $2.73 | $256.62 |
DisclosureSEC source: 0001493152-19-019539 · ownership.xml · nonDerivative · entry 1 Gurrola Sandra M · CIK 0001618457 · SVP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,038 F1 · shares: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. The number of shares to be withheld was determinable on December 19, 2019. No shares were sold in connection with this transaction. Read SEC document |
| November 20, 2019 Filed Nov 21, 2019 01:00 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | Tax withholdingCommon Stock | 95 | $2.62 | $248.90 |
DisclosureSEC source: 0001493152-19-018146 · ownership.xml · nonDerivative · entry 1 Gurrola Sandra M · CIK 0001618457 · SVP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,132 F1 · shares: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. The number of shares to be withheld was determinable on November 20, 2019. No shares were sold in connection with this transaction. Read SEC document |
| October 23, 2019 Filed Oct 23, 2019 23:00 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | Tax withholdingCommon Stock | 94 | $2.88 | $270.72 |
DisclosureSEC source: 0001493152-19-015892 · ownership.xml · nonDerivative · entry 1 Gurrola Sandra M · CIK 0001618457 · SVP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,277 F1 · shares: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. The number of shares to be withheld was determinable on October 23, 2019. No shares were sold in connection with this transaction. Read SEC document |
| September 24, 2019 Filed Sep 24, 2019 23:40 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | Tax withholdingCommon Stock | 454 | $2.28 | $1,035.12 |
DisclosureSEC source: 0001493152-19-014523 · ownership.xml · nonDerivative · entry 1 Gurrola Sandra M · CIK 0001618457 · SVP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,321 F1 · shares: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. The number of shares to be withheld was determinable on September 24, 2019. No shares were sold in connection with this transaction. Read SEC document |
| August 27, 2019 Filed Aug 27, 2019 21:35 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | Tax withholdingCommon Stock | 35 | $2.77 | $96.95 |
DisclosureSEC source: 0001493152-19-013435 · ownership.xml · nonDerivative · entry 1 Gurrola Sandra M · CIK 0001618457 · VP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,775 F1 · shares: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. The number of shares to be withheld was determinable on August 27, 2019. No shares were sold in connection with this transaction. Read SEC document |
| July 30, 2019 Filed Jul 31, 2019 00:00 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | Tax withholdingCommon Stock | 34 | $3.18 | $108.12 |
DisclosureSEC source: 0001493152-19-011370 · ownership.xml · nonDerivative · entry 1 Gurrola Sandra M · CIK 0001618457 · VP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,810 F1 · shares: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. The number of shares to be withheld was determinable on July 30, 2019. No shares were sold in connection with this transaction. Read SEC document |
| June 21, 2019 Filed Jun 24, 2019 21:00 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | Tax withholdingCommon Stock | 34 | $3.47 | $117.98 |
DisclosureSEC source: 0001493152-19-009631 · ownership.xml · nonDerivative · entry 1 Gurrola Sandra M · CIK 0001618457 · VP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,844 F1 · shares: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. The number of shares to be withheld was determinable on June 21, 2019. No shares were sold in connection with this transaction. Read SEC document |
| May 21, 2019 Filed May 21, 2019 23:36 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | Tax withholdingCommon Stock | 35 | $2.89 | $101.15 |
DisclosureSEC source: 0001493152-19-008041 · ownership.xml · nonDerivative · entry 1 Gurrola Sandra M · CIK 0001618457 · VP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,878 F1 · shares: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. The number of shares to be withheld was determinable on May 21, 2019. No shares were sold in connection with this transaction. Read SEC document |
| April 23, 2019 Filed Apr 25, 2019 20:45 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | Tax withholdingCommon Stock | 34 | $3.80 | $129.20 |
DisclosureSEC source: 0001493152-19-005945 · ownership.xml · nonDerivative · entry 1 Gurrola Sandra M · CIK 0001618457 · VP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,913 F1 · shares: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. The number of shares to be withheld was determinable on April 23, 2019. No shares were sold in connection with this transaction. Read SEC document |
| March 26, 2019 Filed Mar 27, 2019 23:30 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | Tax withholdingCommon Stock | 34 | $3.72 | $126.48 |
DisclosureSEC source: 0001493152-19-004045 · ownership.xml · nonDerivative · entry 1 Gurrola Sandra M · CIK 0001618457 · VP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,947 F1 · shares: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. The number of shares to be withheld was determinable on March 26, 2019. No shares were sold in connection with this transaction. Read SEC document |
| March 19, 2019 Filed Mar 21, 2019 20:45 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | GrantCommon Stock | 7,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-19-003713 · ownership.xml · nonDerivative · entry 1 Gurrola Sandra M · CIK 0001618457 · VP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,981 F1 · shares: Represents shares subject to a restricted stock unit award granted under the NTN Buzztime, Inc. Amended 2010 Performance Incentive Plan. The award will vest as to 16.67% of the shares subject to the award on the 6-month anniversary of the grant date and the remaining 83.33% of the shares will vest in 30 substantially equal monthly installments beginning on the 7-month anniversary of the grant date, in each case, subject to the reporting person's continued service to the issuer as of the applicable vesting date. Read SEC document |
| February 26, 2019 Filed Feb 26, 2019 22:00 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | Tax withholdingCommon Stock | 35 | $3.42 | $119.70 |
DisclosureSEC source: 0001493152-19-002608 · ownership.xml · nonDerivative · entry 1 Gurrola Sandra M · CIK 0001618457 · VP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,981 F1 · shares: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. The number of shares to be withheld was determinable on February 26, 2019. No shares were sold in connection with this transaction. Read SEC document |
| January 29, 2019 Filed Jan 30, 2019 01:00 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | Tax withholdingCommon Stock | 34 | $3.18 | $108.12 |
DisclosureSEC source: 0001493152-19-001142 · ownership.xml · nonDerivative · entry 1 Gurrola Sandra M · CIK 0001618457 · VP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,016 F1 · shares: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. The number of shares to be withheld was determinable on January 29, 2019. No shares were sold in connection with this transaction. Read SEC document |
| December 19, 2018 Filed Dec 20, 2018 22:00 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | Tax withholdingCommon Stock | 28 | $2.00 | $56.00 |
DisclosureSEC source: 0001493152-18-017755 · ownership.xml · nonDerivative · entry 1 Gurrola Sandra M · CIK 0001618457 · VP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,050 F1 · shares: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. The number of shares to be withheld was determinable on December 19, 2018. No shares were sold in connection with this transaction. Read SEC document |
| November 20, 2018 Filed Nov 21, 2018 01:00 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | Tax withholdingCommon Stock | 29 | $2.87 | $83.23 |
DisclosureSEC source: 0001493152-18-016582 · ownership.xml · nonDerivative · entry 1 Gurrola Sandra M · CIK 0001618457 · VP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,078 F1 · shares: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. The number of shares to be withheld was determinable on November 20, 2018. No shares were sold in connection with this transaction. Read SEC document |
| October 23, 2018 Filed Oct 24, 2018 12:30 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | Tax withholdingCommon Stock | 28 | $4.32 | $120.96 |
DisclosureSEC source: 0001493152-18-014818 · ownership.xml · nonDerivative · entry 1 Gurrola Sandra M · CIK 0001618457 · VP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,107 F1 · shares: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. The number of shares to be withheld was determinable on October 23, 2018. No shares were sold in connection with this transaction. Read SEC document |
| September 25, 2018 Filed Sep 25, 2018 20:30 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | Tax withholdingCommon Stock | 169 | $4.23 | $714.87 |
DisclosureSEC source: 0001493152-18-013715 · ownership.xml · nonDerivative · entry 1 Gurrola Sandra M · CIK 0001618457 · VP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,135 F1 · shares: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units. The number of shares to be withheld was determinable on September 25, 2018. No shares were sold in connection with this transaction. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.